Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS

被引：0
|
作者：
Fu, Weijun [1 ]
Huang, Honghui [2 ]
Li, Wei [3 ]
An, Gang [4 ]
Cai, Zhen [5 ]
Jin, Jie [5 ]
Wang, Yafei [6 ]
Chim, Chor Sang [7 ]
Qi, Ming [8 ]
Wang, Jianping [9 ]
Song, Yang [10 ]
Jia, Bin [11 ]
Yang, Xue [11 ]
Liu, Wenyu [10 ]
Li, Yunan [12 ]
Zhang, Renyi [13 ]
Hou, Jian [14 ]
Wang, Jianxiang [4 ]
机构：
[1] Shanghai Changzheng Hosp, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China
[3] First Hosp Jilin Univ, Dept Hematol, Oncol Ctr, Changchun, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China
[5] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[6] Tianjin Canc Hosp, Tianjin, Peoples R China
[7] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China
[8] Janssen Res & Dev LLC, Spring House, PA USA
[9] Janssen Res & Dev LLC, Raritan, NJ USA
[10] Janssen Res & Dev LLC, Beijing, Peoples R China
[11] Janssen Res & Dev LLC, Shanghai, Peoples R China
[12] Xian Janssen Pharmaceut Ltd, Med Affairs, Beijing, Peoples R China
[13] Xian Janssen Pharmaceut Ltd, Med Affairs, Shanghai, Peoples R China
[14] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Hematol, Shanghai, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-163
引用
收藏
页码：S125 / S125
页数：1
相关论文
共 50 条
  • [31] Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study
    Sato, Hiroyuki
    Komiya, Yusuke
    Hoshino, Shigeru
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 99 (06) : 786 - 789
  • [32] Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study
    Hiroyuki Sato
    Yusuke Komiya
    Shigeru Hoshino
    International Journal of Hematology, 2014, 99 : 786 - 789
  • [33] Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
    Mateos, M. -V.
    Dimopoulos, M. A.
    Cavo, M.
    Suzuki, K.
    Jakubowiak, A.
    Knop, S.
    Doyen, C.
    Lucio, P.
    Nagy, Z.
    Kaplan, P.
    Pour, L.
    Cook, M.
    Grosicki, S.
    Crepaldi, A.
    Liberati, A. M.
    Campbell, P.
    Shelekhova, T.
    Yoon, S. -S.
    Iosava, G.
    Fujisaki, T.
    Garg, M.
    Chiu, C.
    Wang, J.
    Carson, R.
    Crist, W.
    Deraedt, W.
    Nguyen, H.
    Qi, M.
    San-Miguel, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (06): : 518 - 528
  • [34] Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis
    Hungria, Vania T. M.
    Martinez-Banos, Deborah M.
    Mateos, Maria-Victoria
    Dimopoulos, Meletios A.
    Cavo, Michele
    Heeg, Bart
    Lam, Annette
    Machnicki, Gerardo
    He, Jianming
    Fernandez, Mariana
    BLOOD, 2019, 134
  • [35] Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study
    Dimopoulos, Meletios A.
    Richardson, Paul
    Schlag, Rudolf
    Khuageva, Nuriet K.
    Shpilberg, Ofer
    Kastritis, Efstathios
    Kropff, Martin H.
    Petrucci, Maria Teresa
    Delforge, Michel
    Alexeeva, Julia A.
    Schots, Rik
    Masszi, Tamas
    Mateos, Maria-Victoria
    Deraedt, William
    Liu, Kevin
    Cakana, Andrew
    van de Velde, Helgi
    Miguel, Jesus F. San
    BLOOD, 2008, 112 (11) : 608 - 609
  • [36] Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials
    Gentile, Massimo
    Magarotto, Valeria
    Offidani, Massimo
    Musto, Pellegrino
    Bringhen, Sara
    Petrucci, Maria Teresa
    Gay, Francesca
    Larocca, Alessandra
    Uccello, Giuseppina
    Petrungaro, Annamaria
    Vigna, Ernesto
    Greco, Rosa
    Recchia, Anna Grazia
    Tripepi, Giovanni
    Ria, Roberto
    Di Raimondo, Francesco
    Palumbo, Antonio
    Morabito, Fortunato
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (03) : 244 - 250
  • [37] Bortezomib plus Melphalan and Prednisone for Multiple Myeloma
    Avvisati, Giuseppe
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (24): : 2613 - 2613
  • [38] Bortezomib plus melphalan and prednisone (VMP) in elderly untreated patients with multiple myeloma:: Prognostic factors influencing time to progression
    Mateos, M.-V. M.
    Hernandez, J.-M.
    Hemandez, M.-T.
    Gutierrez, N.-C.
    Palomera, L.
    Fuertes, M.
    Garcia, P.
    Lahuerta, J. J.
    De la Rubia, J.
    Terol, M. J.
    Sureda, A.
    Bargay, J.
    Ribas, P.
    De Arriba, E.
    Alegre, A.
    Oriol, A.
    Carrera, D.
    Garcia-Larana, J.
    Garcia-Sanz, R.
    Bladé, J.
    Prosper, F.
    Esseltine, D.-L.
    Van de Velde, H.
    San-Miguel, J.-F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 148 - 149
  • [39] Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
    Zeng, Xiaohui
    Liu, Qiao
    Peng, Liubao
    Peng, Ye
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Wan, Xiaomin
    Tan, Chongqing
    ADVANCES IN THERAPY, 2021, 38 (05) : 2379 - 2390
  • [40] Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma
    Xiaohui Zeng
    Qiao Liu
    Liubao Peng
    Ye Peng
    Lidan Yi
    Xia Luo
    Sini Li
    Xiaomin Wan
    Chongqing Tan
    Advances in Therapy, 2021, 38 : 2379 - 2390
12345